WASHINGTON, DC, January 3, 2013 – The Alliance for Regenerative Medicine (ARM), the international organization representing the interests of the regenerative medicine community, today announced that 18 ARM members will be presenting at the Biotech Showcase 2013 meeting in San Francisco next week. Featuring company presentations by leading organizations in the industry, Biotech Showcase, produced by EBD Group and Demy-Colton Life Science Advisors, has emerged as a high profile forum for mid-, small- and micro-cap and private companies seeking access to the investor community and potential collaborators. Collectively, the ARM members presenting will showcase the wide scope of progress that is taking place in the regenerative medicine and cell therapy field.
ARM Member Company Presentations:
Tuesday, January 8, 2013
Private Company Track (Mission I Room – Track B):
10:30am Juventas Therapeutics
Public Company Track (Powell Room – Track D):
10:00am Advanced Cell Technology
10:00am Avita Medical (Mission Room II – Track C)
10:30am ReNeuron Group
11:00am Q Therapeutics
11:30am Cytori Therapeutics
2:15pm Shire Regenerative Medicine
3:15pm Athersys, Inc.
Wednesday, January 9, 2013
Powell Room – Track D
10:30am InVivo Therapeutics
In addition, ARM will be hosting two panels comprised of leading experts in the field from 8:00 a.m. to 10:00 a.m. on January 8, 2013. The first panel will provide an in-depth analysis of recent developments in regenerative medicine, with speakers from leading companies and patient advocacy groups. The second panel will cover the outlook for the sector from the investor perspective, and will feature expert healthcare buy side and sell side analysts focused on regenerative medicine and other advanced therapies.
The Biotech Showcase 2013 conference takes place at the Park 55 Wyndham in San Francisco. Although the two panel sessions hosted by ARM are open to the public and do not require paid registration for the conference to attend, paid registration is necessary to gain access to the company presentations and all additional workshops and plenary sessions (http://www.ebdgroup.com/bts/registration/index.php). Space at the panel sessions is limited and it is strongly recommended interested parties RSVP in advance. To learn more and to RSVP, please visit http://www.alliancerm.org/event/arm-state-industry-briefing.
The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based non-profit organization that promotes legislative, regulatory, reimbursement, and financing initiatives necessary to facilitate access to life-giving advances in regenerative medicine. ARM also works to increase public understanding of the field and its potential to transform human healthcare, and provides services to support the growth of its member companies and organizations. Prior to the formation of ARM, there was no advocacy organization operating in Washington, DC to specifically represent the interests of regenerative medicine companies, research institutions, investors, and patient groups supporting more rapid adoption of technologies in our field. To learn more about ARM or to become a member, visit www.alliancerm.org.